Kuchay MS, et al. - By using MRI-derived proton density fat fraction (MRI-PDFF), researchers investigated the impact of empagliflozin (an SGLT-2 inhibitor) on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease (NAFLD). For this investigation, 50 patients with type 2 diabetes and NAFLD were randomized to either the empagliflozin group or the control group for 20 weeks. MRI-PDFF was used to measure change in liver fat. It was observed in the findings that empagliflozin reduced liver fat and improved alanine transaminase levels in patients with type 2 diabetes and NAFLD when included in the standard treatment for type 2 diabetes.